Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks.
Target Price
The average target price of CLYM is 12 and suggests 85% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell